Key result
Pretreatment with atorvastatin 20 mg/day for 3 weeks before coronary bypass surgery significantly reduced postoperative peak levels of IL-6, IL-8, and neutrophil adhesion compared with placebo.
Why the study?
Does preoperative atorvastatin 20 mg/day reduce systemic inflammatory response and perioperative morbidity in patients undergoing coronary artery bypass grafting?
RCT (n=40)
Double-blinded
Randomized
No
Does preoperative atorvastatin 20 mg/day reduce systemic inflammatory response and perioperative morbidity in patients undergoing coronary artery bypass grafting?
Preoperative atorvastatin reduces surrogate markers of systemic inflammation after cardiopulmonary bypass, though it did not significantly alter short-term clinical perioperative morbidity in this small study.
Reduces surrogate inflammatory markers after CABG; leaves open effects on perioperative morbidity in larger trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chello et al. (2006) conducted an RCT in Coronary artery bypass surgery (n=40). Atorvastatin vs. Placebo was evaluated on Systemic inflammatory response (postoperative serum levels of interleukin-6 and interleukin-8, CD11b expression, and neutrophil-endothelial adhesion). Pretreatment with atorvastatin 20 mg/day for 3 weeks before coronary bypass surgery significantly reduced postoperative peak levels of IL-6, IL-8, and neutrophil adhesion compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: